Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW856553X 15 mg vs placebo in Major Depressive Disorder
2006-005578-39Phase 2Terminated
- Sponsor
- GSK
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing GW856553X 15 mg with Placebo (2 arms). Primary endpoint: Primary antidepressant efficacy at Week 6. Started Dec 2006; status: terminated.
02
Drugs
losmapimod
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2006-005578-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005578-39.